Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1α delivery and endogenous cytokine signaling

Zhao, Tiemin; Zhang, Dongsheng; Millard, Ronald W.; Ashraf, Muhammad; Wang, Yigang

doi:10.1152/ajpheart.01134.2008

Cited by 59 publications

(37 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cellular cardiomyoplasty, which seek to replace or regenerate cardiomyocytes through cell transplantation, may be achieved in several ways, at least including transplanting stem cells that differentiate into cardiomyocytes or promote angiogenesis (Segers and Lee 2008), protecting cardiomyocytes as well as vascular endothelial cells via a paracrine mechanism (Takahashi et al 2006) and mobilizing autologous resident stem cells to the site of injury by using cytokines (Zhao et al 2009). Furthermore, electrophysiological stabilization and neural structure, referring to as gap junction and nerve sprouting respectively, are indispensable for evaluating effects and safety of cellular therapy in heart disease, especially in large animal and in humans (Cai et al 2009).…”

Section: Discussionmentioning

confidence: 99%

Transplantation of Adipose Tissue-Derived Stem Cells Overexpressing Heme Oxygenase-1 Improves Functions and Remodeling of Infarcted Myocardium in Rabbits

Yang

Liu

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Adipose tissue-derived stem cells (ADSCs) are a promising source of autologous stem cells that are used for regeneration and repair of infracted heart. However, the efficiency of their transplantation is under debate. One of the possible reasons for marginal improvement in ADSCs transplantation is the significant cell death rate of implanted cells after being grafted into injured heart. Therefore, overcoming the poor survival rate of implanted cells may improve stem cell therapy. Due to limited improvement concerning direct stem cell therapy, gene-transfer methods are used to enhance cellular cardiomyoplasty efficacy. Heme oxygenase-1 (HO-1) can provide various types of cells with protection against oxidative injury and apoptosis. However, exact effects of autologous ADSCs combined with HO-1 on cardiac performance remains unknown. In this study, rabbits were treated with ADSCs transduced with HO-1 (HO-1-ADSCs), treated with non-transduced ADSCs, or injected with phosphate buffered saline 14 days after experimental myocardial infarction was induced, when autologous ADSCs were obtained simultaneously. Four weeks after injection, echocardiography showed significant improvements for cardiac functions and left ventricular dimensions in HO-1-ADSCs-treated animals. Structural consequences of transplantation were determined by detailed histological analysis, which showed differentiation of HO-1-ADSCs to cardiomyocyte-like tissues and lumen-like structure organizations. Apart from improvement in angiogenesis and scar areas, more connexin 43-positive gap junction and greater tyrosine hydroxylase-positive cardiac sympathetic nerves sprouting were observed in the HO-1-ADSCs-treated group compared with ADSCs group. These data suggest that the transplantation of autologous ADSCs combined with HO-1 transduction is a feasible and efficacious method for improving infarcted myocardium.

show abstract

Section: Discussionmentioning

confidence: 99%

Transplantation of Adipose Tissue-Derived Stem Cells Overexpressing Heme Oxygenase-1 Improves Functions and Remodeling of Infarcted Myocardium in Rabbits

Yang

Liu

et al. 2012

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Belonging to the C-X-C motif chemokine family, SDF1 is a constitutively expressed and inducible trophic factor that acts through the CXCR4 receptor (24). Although the potent progenitor cell recruitment mechanism mediated by SDF1 has been explored in preclinical cardiac therapeutic studies (21,33,60), recent clinical trials of cardiac repair based on the use of marrow-mobilizing agents have been disappointing (2), suggesting that the bone marrow-heart axis acting alone may be incapable of achieving robust cardiac repair. The work presented here delineates the therapeutic mechanism underlying the comprehensive muscle-marrow-heart axis, which invokes multiple functionally synergistic trophic factors for cardiac repair.…”

mentioning

confidence: 99%

Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair

Zisa

Shabbir

Mastri

et al. 2011

American Journal of Physiology-Heart and Circulatory Physiology

View full text Add to dashboard Cite

show abstract

“…Therefore, the mechanisms leading to stem/progenitor cell dysfunction need to be better characterized and will provide interesting novel approaches to optimize cellbased treatment approaches. Moreover, strategies to improve cardiac homing and engraftment of stem/progenitor cells may optimize the effect the results of this treatment approach (Pons et al 2008;Pons et al 2009;Tang et al 2009;Zhao et al 2009).…”

Section: Future Directions Of Cell Based-therapy For Ischemic Heart Dmentioning

confidence: 99%

Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy current status and future developments

Templin¹,

Lüscher²,

Landmesser³

2011

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Ischemic heart disease is the main cause of death and morbidity in most industrialized countries. Stem-and progenitor cell-based treatment approaches for ischemic heart disease are therefore an important frontier in cardiovascular and regenerative medicine. Experimental studies have shown that bone-marrow-derived stem cells and endothelial progenitor cells can improve cardiac function after myocardial infarction, clinical phase I and II studies were rapidly initiated to translate this concept into the clinical setting. However, as of now the effects of stem/ progenitor cell administration on cardiac function in the clinical setting have not met expectations. Thus, a better understanding of causes of the current limitations of cell-based therapies is urgently required. Importantly, the number and function of endothelial progenitor cells is reduced in patients with cardiovascular risk factors and/or coronary artery disease. These observations may provide opportunities for an optimization of cell-based treatment approaches. This review provides a summary of current evidence for the role and potential of stem and progenitor cells in the pathophysiology and treatment of ischemic heart disease, including the properties, and repair and regenerative capacities of various stem and progenitor cell populations. In addition, we describe modes of stem/progenitor cell delivery, modulation of their homing as well as potential approaches to "prime" stem/progenitor cells for cardiovascular cell-based therapies.

show abstract

Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1α delivery and endogenous cytokine signaling

Abstract: . Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1␣ delivery and endogenous cytokine signaling.

Cited by 59 publications

References 36 publications

Transplantation of Adipose Tissue-Derived Stem Cells Overexpressing Heme Oxygenase-1 Improves Functions and Remodeling of Infarcted Myocardium in Rabbits

Transplantation of Adipose Tissue-Derived Stem Cells Overexpressing Heme Oxygenase-1 Improves Functions and Remodeling of Infarcted Myocardium in Rabbits

Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair

Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic cardiomyopathy current status and future developments

Contact Info

Product

Resources

About